Among the companies whose shares are expected to actively trade
in Friday's session are Shutterfly Inc. (SFLY), JDA Software Group
Inc. (JDAS) and Metabolix Inc. (MBLX).
Shutterfly said its financial chief was departing to "pursue a
personal passion" with a medical technology company, saying its
chief executive and top accounting executive would split his duties
until it names a successor. Shares were down 5.9% at $22.65 in
after-hours trading.
JDA Software issued a cautious fourth-quarter revenue view
Thursday as the supply-chain company's software and subscription
revenue declined in the Americas. Shares dropped 12% to $28.80
after hours on the weak top-line figure.
Metabolix tumbled 38% to $3.74 in after-hours trading after it
announced that Archer Daniels Midland Co. (ADM) was terminating its
Telles joint venture with the bio-science company.
Cardica Inc. (CRDC) suspended enrollment in a European clinical
trial of its MicroCutter Xpress 30 surgical cutting device because
in a subset of uses it didn't perform satisfactory in thicker
tissue. Shares were down 17% at $1.70 in light after-hours
trading.
Watch List:
Denbury Resources Inc. (DNR) agreed to sell some of its Gulf
Coast-area property to privately held producer Petro Harvester Oil
and Gas for $155 million, continuing its plan to shed noncore
assets this year.
Standard & Poor's Ratings Services upgraded Enterprise
Products Partners LP's (EPD) investment-grade ratings by a notch,
citing the pipeline company's increased scale and diversity and its
high proportion of fee-based revenue.
Slot-machine maker International Game Technology (IGT) confirmed
plans to acquire social-media developer Double Down Interactive LLC
for up to $500 million, placing another big bet on the future
revenue potential of online gamers.
New York & Co. (NWY) expects to post a fourth-quarter loss
amid a bigger-than-anticipated decline in same-store sales and
weaker margins caused by significantly higher levels of
promotions.
Thoratec Corp. (THOR) said Thursday it received a warning letter
from U.S. drug regulators for filing two reports about California
manufacturing plants late.
-Edited by Ian Thomson and Maya Pope-Chappell; write to
ian.thomson@dowjones.com and maya.pope-chappell@dowjones.com